Cancer Patients Decision Making and Family Communication About Secondary Findings From Tumor Genomic Profiling

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

495 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-02-25

Study Completion Date

2026-02-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this protocol is to characterize cancer patients' responses to learning their secondary findings arising from tumor genomic profiling, and the process and outcomes of their decisions to communicate these results to their families.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Decision Support for Women With Breast Cancer

NCT01447771

Breast Neoplasms

TERMINATED NA

Evaluating the Shared Decision Making Process Scale in Cancer Screening Decisions

NCT04601272

Breast Cancer Screening Colon Cancer Screening Prostate Cancer Screening

COMPLETED

Improving Communication Between Cancer Patients & Oncologists

NCT02969031

Cancer

COMPLETED NA

Support Needs and Preferences of Family Caregivers of Lung Cancer Patients

NCT00967083

Lung Cancer

COMPLETED

Health Communication in Families

NCT00597961

Lung Cancer Melanoma Skin Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

For Phase 1 of this study, the investigators will conduct a prospective, observational study with cancer patients undergoing tumor genomic profiling (n = 300) and their family members (anticipated n ≈ 150). Data collection will occur through an embedded mixed methods design, in which both quantitative (i.e., survey) and qualitative (i.e., semi-structured interview) data are collected at the same timepoint in order to obtain a more complete understanding of specific processes and outcomes.

They will be recruited from those who already enrolled in protocol #12-245, and who agree to receive their secondary findings through Consent Part C of this existing protocol.

For Phase 2 of this study, participants (n=500) who have received pathogenic secondary findings through protocol #12-245 will be recruited.

For Phase 3, efforts will be expanded from the adult populations explored in the preceding phases to the experiences of patients affected by pediatric cancers and their families. Cross-sectional mixed methods data from AYA survivors of pediatric cancers (n=50) and adult caregivers of survivors of pediatric cancer (n=50) will be collected.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tumor Genomic Profiling

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

survey

Intervention Type BEHAVIORAL

semi-structured interview

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients (Phase I):

* 18 years of age or older
* Has consented to MSK IRB protocol #12-245, Consent A and Part C
* Has not received secondary findings as a result of MSK IRB protocol #12-245, Consent Part C as per EMR and/or patient report
* Diagnosed with a solid tumor as per EMR and/or clinician judgment
* English-fluent; the surveys were designed and validated in English and are not currently available in other languages. Translation of questionnaires into other languages would require reestablishing the reliability and validity of these measures. Therefore, participants must be able to communicate in English to complete the surveys.

Family members (Phase I):

* 18 years of age or older as per self report
* Nominated by the patient participant as a family member with whom the secondary findings have been shared (spouses/partners are eligible as "family members" for the purposes of this study)
* English-fluent; the surveys were designed and validated in English and are not currently available in other languages. Translation of questionnaires into other languages would require reestablishing the reliability and validity of these measures. Therefore, participants must be able to communicate in English to complete the surveys.

Patients (Phase 2):

* 18 years of age of older
* Has consented to MSK IRB protocol #12-245, Consent Part A and C
* English-fluent; the surveys were designed and validated in English and are not currently available in other languages. Translation of questionnaires into other languages would require reestablishing the reliability and validity of these measures. Therefor, participants must be able to communicate in English to complete the surveys.

AYA Survivors of Pediatric Cancers (Phase 3):

* Age 15 to 30 years old
* Are at least 1 year post-treatment for pediatric cancer (i.e., any cancer diagnosed before age 18)
* Has consented or provided assent to MSK IRB protocol #12-245, Consent Part A and C
* Has received pathogenic secondary findings as a result of MSK IRB protocol #12- 245, Consent Part C as per EMR and/or CGS care provider report
* Participated in a CGS consultation following receipt of secondary findings
* English-fluent; the surveys were designed and validated in English and are not currently available in other languages. Translation of questionnaires into other languages would require reestablishing the reliability and validity of these measures. Therefore, participants must be able to communicate in English to complete the surveys.

Adult Caregivers of Survivors of Pediatric Cancers (Phase 3):

* 18 years of age or older
* Are the caregiver of a child who was treated for pediatric cancer (i.e., any cancer diagnosed before age 18). Caregiver status is based on either: 1) nomination as such by a young adult survivor (i.e., age 18+), 2) having consented on behalf of a minor child (i.e., age \<18) to MSK IRB protocol

#12-245 Part A and C plus self-reported confirmation that s/he is the caregiver for the child, or 3) nomination by the adult who consented on behalf of a minor child (i.e., age \<18) to MSK IRB protocol #12-245 Part A and C plus self-reported confirmation that s/he is the caregiver for the child
* That child is currently alive and at least 1 year post-treatment for pediatric cancer (i.e., any cancer diagnosed before age 18)
* Has consented on behalf of that child, or that child consented, to MSK IRB protocol #12-245, Consent Part A and C
* That child received pathogenic secondary findings as a result of MSK IRB protocol #12-245, Consent Part C as per EMR and/or CGS healthcare provider report
* Participated in a CGS consultation following receipt of secondary findings
* English-fluent; the surveys were designed and validated in English and are not currently available in other languages. Translation of questionnaires into other languages would require reestablishing the reliability and validity of these measures. Therefore, participants must be able to communicate in English to complete the surveys

Exclusion Criteria

* Received genetic testing in the past that resulted in a pathogenic finding or a variant of unknown significance as reported in the EMR.
* Major psychiatric illness or cognitive impairment that in the judgment of the investigator or study staff would preclude study participation
* Any patients who are unable to comply with the study procedures as determined by the study investigators or study staff.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes